Click HERE to download the PDF version

  
Despite exceptional specificity, high potency, and low toxicity, common misconceptions continue to limit the potential of peptide-based therapeutics.

THE FACTS TELL A DIFFERENT STORY

Misconception: Peptides elicit undesired antibody response

Fact: Small-medium synthetic peptides are poor immunogens

Misconception: Peptide therapeutics offer poor pharmacokinetics/ serum stability

Fact: High in vivo concentrations reach target receptors within 60 seconds

Misconception: Limited oral bioavailability makes peptide drugs undesirable

Fact: Advances in subcutaneous and intranasal drug delivery offer incre ... ...